Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poly-N-acetylglucosamine (PNAG) is a linear polysaccharide composed of repeating N-acetylglucosamine (GlcNAc) units linked primarily through β-1,6-glycosidic bonds. It is a key component in the formation of bacterial biofilms, particularly in Staphylococcus aureus and Staphylococcus epidermidis, where it mediates cell adherence to surfaces and intercellular adhesion. PNAG acts as an antigen in bacteria-associated infections and is being studied for potential vaccine development. It also finds application as a hemostatic agent due to its properties that promote blood clotting.
PNAG is a target for anti-biofilm therapies
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poly-N-acetylglucosamine (PNAG).